Back to results
US 9,804,156 B2Granted
Biomarkers for systemic lupus erythematosus
AssigneeLife Technologies Corporation
InventorsNiroshan Ramachandran, Lihao Meng, Gengxin Chen, David Bourdon, Suzy Van Le
Life of this patent
Estimating the term…
Abstract
The disclosure provides SLE biomarkers. The disclosure further provides kits and methods of diagnosing, prognosing, and stratifying subjects with the disease by utilizing SLE biomarkers.
Claims19
A method of determining a biomarker profile in a sample from a subject, comprising:
- contacting a sample comprising serum from a subject with three antibodies, wherein the first two antibodies specifically bind RANTES and the third antibody specifically binds a human autoantibody, wherein the human autoantibody specifically binds transglutaminase, and contacting the sample with a purified antigen comprising transglutaminase;
- and
- detecting a presence or absence of binding, and optionally a quantity of binding, of RANTES with the first two antibodies, and detecting a presence or absence of binding, and optionally a quantity of binding, of the human autoantibody with the third antibody and the purified antigen, and determining a binding profile therefrom.
A method of determining a biomarker profile in a sample from a subject, comprising:
- providing a kit comprising three antibodies, wherein first and second antibodies specifically bind RANTES and a third antibody specifically binds a human autoantibody, wherein the human autoantibody specifically binds transglutaminase,
- contacting a sample comprising serum from a subject with the three antibodies, and contacting the sample with a purified antigen comprising transglutaminase;
- and
- detecting a presence or absence of binding, and optionally a quantity of binding, of RANTES with the first and second antibodies, and detecting a presence or absence of binding, and optionally a quantity of binding, of the human autoantibody with the third antibody and the purified antigen, and determining a binding profile therefrom.
1 more element
A method of determining biomarkers in a sample from a subject, comprising:
- providing a kit comprising three antibodies and a purified antigen, wherein first and second antibodies specifically bind RANTES and a third antibody specifically binds a human autoantibody, wherein the human autoantibody specifically binds transglutaminase and the purified antigen comprises transglutaminase, wherein one of the two antibodies that specifically bind RANTES is immobilized on a solid surface and the purified antigen is immobilized on the solid surface, and wherein the other of the two antibodies that specifically bind RANTES is not immobilized on the solid support and has a first detectable label bound thereto, and wherein a second detectable label is bound to the third antibody;
- contacting a sample comprising serum from a subject with the three antibodies and the purified antigen comprising transglutaminase;
- and
- detecting a presence or absence of binding, and optionally a quantity of binding, of RANTES with the first and second antibodies, and detecting a presence or absence of binding, and optionally a quantity of binding, of the human autoantibody with the third antibody and the purified antigen.
1 more element
Dependencies are inferred from the claim text.